Shayna Sarosiek is a Hematology physician affiliated with Harvard University. OpenAlex indexes 217 publications with 2,170 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
830 Harrison Ave
Moakley, 3rd Floor
Boston, MA 021182905
Telephone
617-638-6428Registry record last updated 27 Sept 2017.
Clinical trials
- Loncastuximab Tesirine in WM
Sponsor: Shayna Sarosiek, MD
- ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
Sponsor: Shayna Sarosiek, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ADC THERAPEUTICS AMERICA, INC.Program year20258 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Genmab U.S., Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
90.9%Kinase inhibitor90.9%Brukinsa100%Part D≥45 patientsBlood & clotting
5.4%Factor Xa inhibitor5.4%Eliquis100%Part D<11 patientsCardiovascular
3.6%Loop diuretic3.6%Torsemide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Journal of Clinical Oncology
2024 - Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib
British Journal of Haematology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”